Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
NCT05912387
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
PSC is a liver disease that has no medical cure. Patients with PSC are at a greatly increased risk of cancer and infection. Additionally, many patients require a liver transplant. Progress towards a cure has been severely limited by an incomplete understanding of why patients develop PSC. The investigators aim to close this gap by conducting a pilot human study in patients with PSC, using statin therapy as a model
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Primary Sclerosing Cholangitis
- Inflammatory Bowel Diseases
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Stanford University
- Last updated on ClinicalTrials.gov
- February 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Stanford University · Stanford, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.